MeSH tree: D23.050.285
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after treatment, particularly ...
Dec 19, 2025
0
14
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools. While the traditional staging systems, such as the TNM classification, focus on anatomical ...
Dec 13, 2025
0
13
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is ...
Dec 10, 2025
0
22
Researchers at Karolinska Institutet in Sweden and the RIKEN Center for Brain Science in Japan have identified two receptors in the brain that control the breakdown of amyloid beta, a substance that accumulates in Alzheimer's ...
Nov 29, 2025
0
113
The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of postoperative recurrence and ...
Nov 24, 2025
0
14
A multicenter clinical study in Austria has shown that a new, highly precise ultrasound approach can successfully target and treat early prostate cancer while preserving patients' quality of life. Tumor control was achieved ...
Nov 18, 2025
0
24
Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and an immune checkpoint ...
Oct 27, 2025
0
17
Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce blood cholesterol levels and high blood pressure. But can it also help slow down the growth of ...
Oct 23, 2025
0
19
Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, ...
Oct 22, 2025
0
15
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
Oct 19, 2025
0
174
